Cellectis (NASDAQ:CLLS) Stock Price Crosses Below 200 Day Moving Average - Time to Sell?

Key Points

• Cellectis shares fell below their 200‑day moving average, trading as low as $3.73 versus a 200‑day MA of $4.02 and down roughly 6.8% on the session.
• Analyst sentiment is mixed but leans positive—the consensus is a "Moderate Buy" with an average target of $6.75 (one Strong Buy, four Buy, one Sell), while Weiss Ratings maintains a "sell (d-)."
• The company reported Q1 EPS of ($0.26) that missed estimates while revenue of $15.5M beat expectations, and remains unprofitable with a negative net margin (~84.9%) and negative ROE; market cap is about $374M.

Shares of Cellectis S.A. (NASDAQ:CLLS - Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.02 and traded as low as $3.73. Cellectis shares last traded at $3.73, with a volume of 22,405 shares trading hands.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Citizens Jmp reiterated a "market outperform" rating and issued a $8.00 price objective on shares of Cellectis in a research report on Tuesday, April 14th. Jefferies Financial Group assumed coverage on Cellectis in a research report on Tuesday, February 17th. They issued a "buy" rating and a $7.00 price objective for the company. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Cellectis in a research report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $6.75.

Cellectis Trading Down 6.8%

The company has a market capitalization of $374.26 million, a P/E ratio of -5.57 and a beta of 2.91. The stock's 50 day moving average is $3.69 and its 200-day moving average is $4.02. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.62 and a quick ratio of 1.62.

Cellectis (NASDAQ:CLLS - Get Free Report) last announced its quarterly earnings data on Thursday, March 19th. The biotechnology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.16). The firm had revenue of $15.50 million for the quarter, compared to analysts' expectations of $10.74 million. Cellectis had a negative net margin of 84.92% and a negative return on equity of 69.38%.

Hedge Funds Weigh In On Cellectis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP lifted its position in Cellectis by 1,610.3% during the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company's stock valued at $864,000 after buying an additional 168,038 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Cellectis during the fourth quarter valued at approximately $15,385,000. Global Retirement Partners LLC bought a new position in shares of Cellectis during the fourth quarter valued at approximately $34,000. Millennium Management LLC increased its stake in shares of Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company's stock valued at $165,000 after purchasing an additional 22,080 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in shares of Cellectis during the third quarter valued at approximately $633,000. Hedge funds and other institutional investors own 63.90% of the company's stock.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company's core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.